Mirabegron Heumann (Mirabegron)

The drug selectively activates β3‑adrenergic receptors on the detrusor muscle of the bladder. This activation relaxes the muscle during the storage phase, allowing the bladder to hold more urine and decreasing episodes of urgency and leakage.

The specific dose and titration schedule are determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mirabegron in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and works by relaxing bladder muscle rather than blocking muscarinic receptors. It may be preferred when anticholinergics cause dry mouth, constipation, or cognitive side effects, but individual response varies.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Mirabegron Heumann is taken orally as a tablet, usually once daily with or without food. The exact timing and whether it is taken with meals should follow the prescriber’s guidance.

Serious risks include significant hypertension, angioedema, and urinary retention. Patients should be educated to seek immediate medical attention if they experience severe headache, swelling of the face or throat, or inability to urinate.

Individuals with uncontrolled hypertension, severe renal impairment, or known hypersensitivity to Mirabegron should avoid the medication. It is also contraindicated when used together with strong CYP2D6 or CYP3A4 inhibitors that cannot be discontinued.